Výsledky vyhledávání - "N. Batista López"

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Oncotarget
Scopus-Elsevier
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Oncotarget, 2018, vol. 9, núm. 86, p. 35687-35704
Articles publicats (IdIBGi)
Martin Castillo, Begoña Pernas, Sonia Dorca, Joan Álvarez, Isabel Martínez, Susana Pérez Garcia, Jose Manuel Batista López, Norberto Rodríguez Sánchez, César A. Amillano, Kepa Domínguez, Severina Luque, Maria Stradella, Agostina Morilla, Idoia Viñas, Gemma Cortés, Javier Cuyàs, Elisabet Verdura, Sara Fernández Ochoa, Álvaro Fernández Arroyo, Salvador Segura Carretero, Antonio Joven, Jorge Pérez, Elsa Bosch, Neus Garcia, Margarita López Bonet, Eugeni Saidani, Samiha Buxó Pujolràs, Maria Menéndez Menéndez, Javier Abel 2018 A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study Oncotarget 9 86 35687 35704
DUGiDocs – Universitat de Girona
instname

The METTEN study assessed the efficacy, tolerability, and safety of adding metformin to neoadjuvant chemotherapy plus trastuzumab in early HER2-positive breast cancer (BC). Women with primary, non-metastatic HER2-positive BC were randomized (1:1) to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d91433b4b411119bbcc0dd3f3b0d404
https://doi.org/10.18632/oncotarget.26286

Zobrazit plný text záznamu

Abstract P1-10-01: Safety and efficacy of neoadjuvant metformin with trastuzumab and chemotherapy in women with HER2-positive early breast cancer: A randomized, open-label, multicenter, phase 2 trial

Publikováno v: Cancer Research. 78:P1-10

Background: Epidemiological, pre-clinical, and window-of-opportunity trials have suggested that the anti-diabetic drug metformin (MET) may have beneficial effects on breast cancer (BC). The clinical relevance of combining MET with current standards o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c754dd408a2d38f1fc12e9d5a131b219
https://doi.org/10.1158/1538-7445.sabcs17-p1-10-01

Zobrazit plný text záznamu

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Autor: Patrick Urban, M. Campone, Petr Krivorotko, Cristian Massacesi, Roberto Hegg, Arlene Chan, JT Beck, M. Ramos Vazquez, L.Y. Dirix, Alexey Manikhas, E. Di Tomaso, Suzette Delaloge, Miguel Martin, Mikhail Shtivelband, N. Batista López, M. Ruiz Borrego, Joyce O'Shaughnessy, Qamar J. Khan, S. Goteti

Publikováno v: Annals of Oncology. 28:313-320

Background Phosphatidylinositol 3-kinase (PI3K) pathway activation in preclinical models of breast cancer is associated with tumor growth and resistance to anticancer therapies, including paclitaxel. Effects of the pan-Class I PI3K inhibitor buparlis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6eec808f430190bc71dc11cab4d3eb0
https://doi.org/10.1093/annonc/mdw562

Zobrazit plný text záznamu

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

Publikováno v: Aging (Albany NY)
Aging, 2019, vol. 11, num. 9, p. 2874-2888
Articles publicats (IdIBGi)
Cuyàs, Elisabet Fernández-Arroyo S Buxó Pujolràs, Maria Pernas, Sonia Dorca, Joan Álvarez, Isabel Martínez, Susana Pérez-Garcia, Jose Manuel Batista López, Norberto Rodríguez Sánchez, César A. Amillano, Kepa Domínguez, Severina Luque, Maria Morilla, Idoia Stradella, Agostina Viñas, Gemma Cortés, Javier Verdura, Sara Brunet i Vidal, Joan López Bonet, Eugeni Garcia, Margarita Saidani, Samiha Joven, Jorge Martin Castillo, Begoña Menéndez Menéndez, Javier Abel 2019 Metformin induces a fasting-and antifolate-mimicking modification of systemic host metabolism in breast cancer patients Aging 11 9 2874 2888
DUGiDocs – Universitat de Girona
instname
Scientia
Recercat. Dipósit de la Recerca de Catalunya
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)

Homocisteïna; Càncer de mama; Dieta cetogènica Homocisteína; Cáncer de mama; Dieta cetogénica Homocysteine; Breast cancer; Ketogenic diet Certain dietary interventions might improve the therapeutic index of cancer treatments. An alternative to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::040815679dc0ccbdaacfb1266601c504
https://pubmed.ncbi.nlm.nih.gov/31076561

Zobrazit plný text záznamu

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Journal of Clinical Medicine
Journal of Clinical Medicine (JCM), 2019, vol. 8, núm. 12, p. 2180
Articles publicats (IdIBGi)
DUGiDocs – Universitat de Girona
instname
Recercat. Dipósit de la Recerca de Catalunya

Metformina; Ki67; Càncer de mama Metformina; Ki67; Cáncer de mama Metformin; Ki67; Breast cancer The proliferative capacity of residual breast cancer (BC) disease indicates the existence of partial treatment resistance and higher probability of tum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7c9c335b429a690ac14b6aed56bbb21
https://doi.org/10.3390/jcm8122180

Zobrazit plný text záznamu

Plný text ve formátu HTML

Plasma levels of trastuzumab in gastric cancer: Case report

Autor: N Batista-López, J González-García, G J Nazco-Casariego, F Guttiérrez-Nicolás, B Alonso-Alvarez

Publikováno v: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 23(8)

Introduction The use of trastuzumab with a fluoropyrimidine and platinum compound is currently the standard first-line treatment of patients with metastatic HER2-positive gastric cancer, but it appears that serum levels of trastuzumab determine the c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7339f510ca3c3d506bf0c8906894cc07
https://pubmed.ncbi.nlm.nih.gov/27664112

Zobrazit plný text záznamu

Zinc, copper, manganese, and iron in chronic alcoholic liver disease

Autor: O. Hernandez-Torres, Francisco Santolaria-Fernández, N. Batista-López, M. Molina-Perez, F. Rodríguez-Moreno, L. Galindo-Martín, Emilio González-Reimers

Publikováno v: Alcohol. 14:39-44

Ethanol consumption and/or liver damage may alter liver content of several trace elements, as iron, zinc, copper, and manganese. This alteration may play a role on ongoing liver fibrogenesis. Based on these facts we have determined liver, serum, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9385a401d3e9106548632721b38a2416
https://doi.org/10.1016/s0741-8329(96)00103-6

Zobrazit plný text záznamu

Harris lines and ethanol consumption during growth period

Autor: F. Rodríguez-Moreno, Francisco Santolaria-Fernández, A. Moreno-García, N. Batista-López, Emilio González-Reimers

Publikováno v: International Journal of Anthropology. 8:21-25

Harris lines represent episodes of growth arrest followed by recovery, thus reflecting episodes of mismatched imbalance between energy intake and energy expenditure. Consumption of ethanol during the growth period — formerly extended in our wine-pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::761b2620f6f690f0a7fdcffcfac73c1f
https://doi.org/10.1007/bf02447639

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání